Balyasny Asset Management LLC Rapt Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$6.87 - $26.45 $398,150 - $1.53 Million	57,955 New	57,955 $520,000
Q2 2023 Aug 14, 2023	BUY	$16.06 - $21.61 $696,056 - $936,599	43,341 Added 42.8%	144,605 $2.7 Million
Q1 2023 May 15, 2023	BUY	$17.19 - $30.8 $1.74 Million - $3.12 Million	101,264 New	101,264 $1.86 Million
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $958,248 - $1.28 Million	-32,483 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$29.86 - $39.47 $390,897 - $516,701	-13,091 Reduced 28.72%	32,483 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$17.99 - $40.02 $819,876 - $1.82 Million	45,574 New	45,574 $1.45 Million

104

49.4M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $33.8M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.